FibroGen granted FDA Fast Track Designation for pulmonary fibrosis med

FibroGen announced that the U.S. FDA has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis. This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.

https://thefly.com/landingPageNews.php?id=2789331